ArticleClinical rheumatology2026
The joint associations of TyG index and hsCRP with hyperuricemia among Chinese adults: a cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimThis study investigated the independent and combined effects of the triglyceride glucose (TyG) index and high-sensitivity C-reactive protein (hsCRP) levels on hyperuricemia (HUA), aiming to provide a scientific basis for early identification and intervention.
methodsParticipants were categorized into four groups based on the median TyG index (8.66) and the established clinical cutoff for hsCRP (1 mg/L). Restricted cubic spline (RCS) model was employed to test for nonlinear trends between HUA and both the TyG index and hsCRP levels separately. A multivariable logistic regression model was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for HUA across the TyG-hsCRP groups, with the low TyG/low hsCRP group serving as the reference.
resultsThe study included 5,303 participants with a mean age of 49.31 ± 12.13 years, of whom 3,063 (57.76%) were male. RCS model analysis revealed a linear association between the TyG index and HUA (P
conclusionThe combined elevation of both TyG index and hsCRP levels significantly increases the risk of hyperuricemia, demonstrating a clinically meaningful compound association. This association supports the utility of dual-marker assessment for precise early screening and improved risk stratification. Key Points • Elevated TyG index and increased hsCRP levels jointly exhibit a significant combined association, correlating with the risk of hyperuricemia (OR = 2.25), suggesting that combined assessment of these two markers in clinical practice may more effectively identify high-risk individuals than evaluating either marker alone. • The TyG index exhibits a linear correlation with risk, whereas hsCRP shows a nonlinear association, suggesting that the two may participate in disease development through distinct mechanisms. This provides clues for exploring differentiated intervention targets. • The combined effect is particularly pronounced in women and individuals under 65 years of age. In clinical screening, dual-marker combined testing can be prioritized for specific populations to achieve more precise early prevention.
Indexed as
Identifiers
41746469What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.